Allogeneic hematopoietic cell transplantation for adults with ALL

Bone Marrow Transplantation
Ra Larson

Abstract

ALL is a heterogeneous disease, and outcomes vary by patient age, immunophenotype and clinical, cytogenetic and molecular features. Modern treatment strategies use a risk-adapted approach. The optimal post-remission therapy for adults with ALL remains unclear. Available data indicate no consensus as to whether there is an advantage to allogeneic hematopoietic cell transplant (Allo-HCT) over chemotherapy for the consolidation of adults with ALL with standard risk features while in the first CR (CR1). However, Allo-HCT is recommended in CR1 for patients with high-risk ALL, for those in a second CR (CR2) and for certain other subsets of patients with this disease.

References

Jan 1, 1991·Journal of Inherited Metabolic Disease·E A KvittingenA Flatmark
Dec 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C SebbanD Maraninchi
Sep 20, 2002·Blood·Hervé DombretUNKNOWN Groupe d'Etude et de Traitement de la Leucémie Aiguë Lymphoblastique de l'Adulte (GET-LALA Group)
Dec 19, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·O RingdénF Frassoni
Mar 26, 2003·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Derek L StirewaltJerald P Radich
Apr 15, 2003·Leukemia & Lymphoma·Gerlinde EgererAnthony D Ho
Jul 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael G KiehlOlle Ringden
Sep 9, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Xavier ThomasDenis Fiere
Oct 1, 2005·Blood·Monika BrüggemannUNKNOWN German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia
Oct 11, 2005·Critical Reviews in Oncology/hematology·Dietger NiederwieserHaifa Al-Ali
Dec 14, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Masamitsu YanadaUNKNOWN Japan Adult Leukemia Study Group
Jan 10, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Theresa HahnPhilip L McCarthy
Apr 25, 2006·Bone Marrow Transplantation·A R Mato, S M Luger

❮ Previous
Next ❯

Citations

Nov 19, 2011·Hematology/oncology Clinics of North America·Jae H ParkRenier Brentjens
Jan 29, 2009·International Journal of Cancer. Journal International Du Cancer·Robert W Caughey, Karin B Michels
Jul 25, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Mohammad BakrMahmoud Aljurf
Aug 29, 2009·Current Opinion in Oncology·Ryan J Mattison, Richard A Larson
Jun 6, 2014·Crisis·Wendi F CrossMadelyn S Gould

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.